Form 4: Monopar Therapeutics Executive Andrew Cittadine Reports Stock Purchases

Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics, reported the acquisition of common stock in multiple transactions between June 13 and June 17, 2024.

Summary

• Andrew Cittadine, the Chief Operating Officer of Monopar Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• The report indicates that Cittadine acquired shares of Monopar Therapeutics common stock through a series of transactions.
• On June 13, 2024, Cittadine purchased 12,000 shares at a price of $0.91 per share.
• On June 14, 2024, Cittadine purchased 12,000 shares at a weighted average price of $0.9313 per share.
• On June 17, 2024, Cittadine purchased 12,000 shares at a price of $0.8999 per share.
• Following these transactions, Cittadine directly owns 153,624 shares of Monopar Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying is generally seen as a positive sign, but the scale of the purchases is relatively small.

Positives

• The COO's stock purchases could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of the stock market, providing transparency into the transactions of company insiders. Investors often monitor these filings to gain insights into management's perspective on the company's value.

Stakeholder Impact

• The stock purchases by a key executive could positively influence shareholder sentiment.

Key Dates